Clinical trials: Cirrhosis Liver
Hepatitis B
Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa
Viral hepatitis kills nearly one million people each year, even though effective treatment exists. The aim of this study is to establish a treatment protocol for hepatitis B, which is simple and cheap enough to be implemented in…
- Trial name
- NCT02344498
- Testing
- Tenofovir disoproxil
- Where
- Ethiopia
- Volunteers
- 7,350 people
- Sponsor
- Oslo University Hospital
Liver Cirrhoses
Risk Factors of Liver Fibrosis Among First Degree Relatives of Patients With NASH Related Cirrhosis (NRC)
The study aim to identify the risk factors of liver fibrosis among first degree relatives. This study consists of 2 parts (Cross Sectional and Case Control Study).
- Trial name
- NCT04057287
- Testing
- No intervention
- Where
- India
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
Hepatitis B, Chronic, Liver Fibrosis
Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection
This study will examine whether 12 month treatment with entecavir(Baraclude®) has an effect on changes of liver stiffness measurement (LSM) and of hyaluronan measurement in patients with chronic hepatitis B infection.
- Trial name
- INFIRE (NCT01341106)
- Testing
- Treatment with entecavir(Baraclude®)
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- RWTH Aachen University
Hepatic Encephalopathy, Cirrhosis
The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
The purpose of the study is to evaluate if rifaximin alone or rifaximin plus lactulose delays the onset of hepatic encephalopathy (HE) in participants with cirrhosis who have had a previous episode of HE.
- Trial name
- NCT01842581
- Testing
- Rifaximin, Lactulose
- Where
- 43 sites in United States
- Volunteers
- 222 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis, Liver Cirrhosis
Hepatocyte-specific Versus Extracellular Contrast Agents for Liver MRI: Prospective, Intra-individual Comparison of Diagnostic Performance for Hepatocellular Carcinoma
Adult patients with chronic hepatitis B and cirrhosis of any etiology who are found to have suspected liver cancer are potentially eligible for the study.
- Trial name
- NCT03892681
- Testing
- hepatocyte-specific contrast agent, extracellular contrast agent
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Yonsei University
NAFLD, Inflammatory Bowel Diseases
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Non-alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disease characterized by the presence of more than 5% of steatosis in hepatocytes of individuals who consume little or no alcohol.
- Conditions
- NAFLD, Inflammatory Bowel Diseases, Steatosis, Fibrosis, Liver
- Trial name
- PONI (NCT06814600)
- Testing
- Transient elastometry
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Cirrhosis, Liver, Metagonimiasis
Synbiotics Interventions for Managing Cirrhosis and Its Complications
Background Liver cirrhosis is commonly accompanied by intestinal dysbiosis and metabolic defects. Many clinical trials have shown microbiota-targeting strategies represent promising interventions for managing cirrhosis and its…
- Trial name
- NCT05687409
- Testing
- Entecavir 0.5 mg, A 10-g packet of lactulose oral solution and three capsules of probiotics, A 10-g packet of glucose oral solution and three capsules of starch
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Fibrosis, Liver
Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
- Trial name
- NCT05567614
- Testing
- Liver Fibroscan
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Assiut University
Liver Cirrhosis
Fructans, Lactitol and Lactose in Minimal Hepatic Encephalopathy
As an alternative for the treatment of Minimal Hepatic Encephalopathy (MHE) Agave fructans have shown prebiotic effects, and have shown to improve function of the digestive system, control and induce glycemic effect satiety.
- Trial name
- NCT02022137
- Testing
- Red cereal bar, Green cereal bar, White cereal bar
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Cirrhosis
Telomeres Parameters in Cirrhosis
There are several factors that influence telomere length in patients with cirrhosis, such as metabolic derangements and infectious etiologies, The aim of the study is to compare telomere length and other parameters related to…
- Trial name
- NCT02131831
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Meir Medical Center
Acute Kidney Injury, Cirrhosis
Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices
We will include patients with EV and EVB. They will be randomized to EVL vs. NSBB for primary prevention And EVL+long-term NSBB vs. EVL+short-term NSBB for secondary prevention. 150 patients will be included in a 3-year period.
- Conditions
- Acute Kidney Injury, Cirrhosis, Esophageal Varices
- Trial name
- AKI (NCT04074473)
- Testing
- propranolol, Esophageal varice ligation, DC propranolol
- Where
- Taiwan
- Volunteers
- 170 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Liver Cirrhosis
Evaluation of Lactoferrin, Procalcitonin and Aution® Urine Dipsticks for the Diagnosis of Spontaneous Bacterial Peritonitis in Cirrhotic Patients
Bacterial infections are a major cause of mortality in cirrhotic patients in the context of gastrointestinal bleeding or spontaneous bacterial peritonitis (SBP).
- Trial name
- NCT02798939
- Where
- France
- Volunteers
- 123 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
NASH, Cirrhosis, Liver
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical…
- Trial name
- NCT05500222
- Testing
- Resmetirom
- Where
- 141 sites in United States, Belgium and 7 more
- Volunteers
- 845 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Decompensated Cirrhosis, Fecal Microbiota Transplantation
Fecal Microbiota Transplantation for Decompensated Cirrhosis
Imbalance of gut bacteria is suspected to play a key role driving the progression of cirrhosis and there is hope manipulation of these bacteria may be beneficial.
- Trial name
- FMTDC (NCT03014505)
- Testing
- FMT, traditional treatments
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chengdu Medical College
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use.
- Trial name
- NCT03712280
- Testing
- MNK6106, Rifaximin
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- Mallinckrodt
Cirrhosis, Liver, Ascites Hepatic
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide on the renal response in patients with liver cirrhosis and refractory ascites for a maximum exposure duration of 48 hours, through a…
- Trial name
- ULA04 (NCT04311489)
- Testing
- Ularitide
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- University of Aarhus
Cirrhosis, Liver, Portal Hypertension
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study
The LIVE-SMART supplementary study will assess social determinants of health (income, education, neighborhood deprivation), financial burden (out-of-pocket costs, productivity loss), financial distress (patient and…
- Trial name
- LiveSMART (NCT07140120)
- Where
- 3 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Michigan
HCC
ELRIAH Score: A Simple Score for HCC Risk Stratification in CHC Patients With Cirrhosis or Advanced Liver Fibrosis Who Achieved SVR Following DAA Therapy
aimed to develop a scoring system to assess risk of developing HCC in a large cohort of chronic hepatitis C (CHC) patients with advanced hepatic fibrosis (F3) or cirrhosis (F4) with sustained virological response (SVR) after…
- Trial name
- NCT04173520
- Testing
- DDA
- Volunteers
- 2,326 people
- Sponsor
- Egyptian Liver Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.